Showing results (1571-1580 of 7,923) with videos related to

Sort By:
Pageof 793
Nihon Kyobu Shikkan Gakkai Zasshi|April 1, 1993
[A case of ceftazidime-induced pneumonitis]K Suzuki, T Inagaki, S Adachi, et al.
Neuroscience Letters|April 2, 1993
Neuropeptide Y innervation in the spinal nucleus of bulbocavernosus of the ratM Kawano, O Sugita, S Inagaki, et al.
Biocontrol Science|March 28, 2014
Evaluation of a rapid oral bacteria quantification system using dielectrophoresis and the impedance measurementKatsuhiko Hirota, Satoru Inagaki, Ryo Hamada, et al.
Nihon Hoshasen Gijutsu Gakkai Zasshi|March 22, 2013
[Usefulness of criterion on which to operate coronary computed tomography angiography used dual source computed tomography comparisons with exposure dose of prospective electrocardiogram high-pitch spiral mode, low-pitch spiral mode, and step and shoot mode]Tomokazu Shohji, Sousuke Higuchi, Tetsuya Iida, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2013
Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancerNoriko Inagaki, Kayoko Kibata, Takeshi Tamaki, et al.
Microbial Pathogenesis|January 26, 2016
Treponema denticola invasion into human gingival epithelial cellsSatoru Inagaki, Ryuta Kimizuka, Eitoyo Kokubu, et al.
Angewandte Chemie (International Ed. in English)|December 4, 2014
Air-stable cationic gold(I) catalyst featuring a Z-type ligand: promoting enyne cyclizationsFuyuhiko Inagaki, Chiaki Matsumoto, Yasuhiko Okada, et al.
Case Reports in Immunology|November 18, 2020
A Case of Prolonged Catatonia Caused by Sjögren's SyndromeTakahiko Inagaki, Kotaro Kudo, Naoki Kurimoto, et al.
International Archives of Allergy and Applied Immunology|January 1, 1988
Inhibition of vascular permeability increase in mice. An additional anti-allergic mechanism of glucocorticoidsN Inagaki, T Miura, H Nagai, et al.
Journal of Diabetes Investigation|August 25, 2017
Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory studyNobuya Inagaki, Hiroki Sano, Yoshifumi Seki, et al.
Pageof 793